022 Meds Management: Drugs monitoring suite

022 Meds Management: Drugs monitoring suite

The Drugs Monitoring Suite searches are designed to identify patients on various medication who require monitoring, and whether that monitoring is due. 
Features include: 
  1. Empowers staff to check for single drugs’ monitoring, or drugs across all patients
  2. Instantly see which patients are due monitoring for a range of tests including LFTs, eGFRs, BPs and more
  3. Patients who are due for monitoring on two or more drugs are identified in a distinct report to enable focused recall
  4. A separate folder for drugs with undefined monitoring requirements is included
What follows is a description of each folder and an explanation of its content.
Notes
The Drugs Monitoring Suite folder forms part of 022 Meds Management


Info
PCIT do not recommend running the Drugs monitoring suite top-level folder. Instead, run one of the lower folders e.g. Actions.

These folders can be run either using today's date or a relative run date to assess Practice monitoring compliance over time.

Actions

Due monitoring single drug - every patient who appears in this report appears on only one of the drug groups. See below (Single Drug Monitoring Overdue) for the full list of drugs that are included.
Due monitoring two or more drugs - every patient who appears in this search appears on two or more drug groups. This list has been split out separately in case the required monitoring of two or more drugs overlaps - in this way, there is less chance of having to recall the patient multiple times.
Notes
These two reports are non-specific and will show the latest results for every test - this does not mean each patient needs every test.

Potential Monitoring

Drug (report name)
Monitoring
Flutamide (established)
LFT every 12 months
Naltrexone
LFT every 12 months
Pioglitazone
LFT every 12 months
Piracetam
If latest eGFR less than 60, carry out a CrCl
Propylthiouracil
LFT every 12 months
Rilizole (established)
LFT every 12 months

These drugs have poorly-defined monitoring requirements, typically "as clinically indicated". We have put a 12 month check on whichever monitoring is required.

Single Drug Monitoring Overdue

Use these reports to monitor individual drugs. Note that patients who appear in two or more drugs will instead appear in the Due monitoring two or more drugs
The following time periods are used to flag patients:
Time period of required monitoring:
Patient will be flagged from:
Every 12 months
10 months
Every 6 months
22 weeks
Every 3 months
10 weeks
Every 1 month
3 weeks
Info
Where a drug is "established", this means the patient has been on it for 2 or more consecutive years
Drug (report name)
Monitoring
ACEi ARB (with Heart Failure)
U&Es every 6 months
ACEi ARB
U&Es every 12 months
Acetazolamide
FBC and U&Es every 12 months
Alfacalcidol
U&Es every 1 months and LFT every 12 months
Amiodarone
U&Es and LFTs every 6 months
Amisulpiride
FBC and U&Es and LFT every 12 months
Atomoxetine
BP and BMI and Pulse every 6 months
Azathioprine
FBC and U&Es and LFT every 3 months
Balsalazide
U&Es every 12 months
Carbamazepine
FBC and LFT every 12 months, U&Es every 6 months
Ciclosporin levels
This report will show every patient's latest ciclosporin level
Ciclosporin (systemic)
FBC and U&Es and LFT every 1 month
Cinacalcet
Calcium every 3 months
Clonidine
BP and BMI and Pulse every 6 months
Cyproterone
FBC every 12 months and LFT every 3 months
Dapsone
FBC every 3 months
Dexamfetamine
BP and BMI and Pulse every 6 months
Digoxin
U&Es every 12 months
Disulfiram
LFT every 6 months
Diuretics
U&Es every 12 months
Dronedarone (established)
U&Es and LFT every 12 months
Dronedarone (Unestablished)
U&Es every 12 months and LFT every 3 months
Flutamide (Unestablished)
LFT every 1 month
Guanfacine
BP and BMI and Pulse every 6 months
Hydroxycarbamide
FBC and U&Es and LFT every 3 months
Hydroxychloroquine
U&Es and LFT every 12 months
Ibandronic acid
U&Es, Bone profile, phosphate and magnesium every 12 months
Ketoconazole
LFT every 3 months
Leflunomide (no methotrexate)
FBC and U&Es and LFT every 3 months
Lisdexamfetamine
BP and BMI and Pulse every 6 months
Lithium
U&Es, TSH and calcium every 6 months, lithium every 4 months
Mercaptopurine
FBC and U&Es and LFT every 3 months
Mesalazine
FBC and U&Es and LFT every 6 months
Metformin
U&Es every 12 months
Methotrexate (no leflunomide)
FBC and U&Es and LFT every 3 months
Methotrexate (with leflunomide)
FBC and U&Es and LFT every 1 months
Methylphenidate
BP and BMI and Pulse every 6 months
Minocycline
LFT every 3 months
Mirabegron
BP every 6 months
Mycophenolate
FBC and U&Es and LFT every 3 months
Nitrofurantoin
LFT every 12 months
NSAID
FBC and U&Es every 12 months
Olanzapine
FBC and U&Es and LFT every 12 months
Penicillamine
FBC and U&Es and LFT every 3 months
Phenytoin
FBC and LFT every 12 months
Quetiapine
FBC and U&Es and LFT every 12 months
Rilizole (Unestablished)
LFT every 3 months
Risperidone
FBC and U&Es and LFT every 12 months
Sirolimus 
FBC and U&Es and LFT every 12 months
Sodium valproate monitoring
FBC and U&Es and LFT every 12 months
Spironolactone (HF or ACEi/ARB)
U&Es every 3 months
Spironolactone (not HF or ACEi/ARB)
U&Es every 12 months
Sulfasalazine (Established)
U&Es every 12 months
Sulfasalazine (Unestablished)
FBC and U&Es and LFT every 3 months
Tacrolimus
FBC and U&Es and LFT every 12 months
Testosterone
FBC every 12 months and PSA monitoring if male and 45 or over
Theophylline
U&Es every 12 months
Tolcapone
LFT every 2 months

Initial release April 2025
    • Related Articles

    • 022 Meds Management Overview

      Overview The EMIS search folder 022 Meds Management brings together groups of searches and reports under the umbrella of medicines monitoring. This set of searches cover an expanding range of topics. Additional support articles linked below will help ...
    • 022 Meds Management: OneDrug Risk

      The OneDrugRisk searches are designed to identify patients who have: Monitoring requirements outstanding Hazard scenarios present Quality issues identified The OneDrugrisk folder forms part of 022 Meds Management In order to understand the ...
    • 022 Meds Management: HRT

      The Hormone Replacement Therapy searches are designed to identify patients on HRT medication who require annual monitoring. The HRT folder forms part of 022 Meds Management Patients on HRT should be monitored at least annually. The report pulls out ...
    • 022 Meds Management: Insomnia

      The Insomnia searches are designed to identify patients who have been prescribed a Z drug (Zopiclone or Zolpidem) in the last 3 months to help monitor prescribing safely. The Insomnia folder forms part of 022 Meds Management The search contains ...
    • 022 Meds Management: Bisphosphonate

      The Bisphosphonate prescribing searches are designed to identify patients who are currently prescribed a bisphosphonate medication on repeat, and have had an issue in the last 3 months. The Bisphosphonate folder forms part of 022 Meds Management ...